Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.

[1]  A. Vitale,et al.  Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) , 2016 .

[2]  F. Mannelli,et al.  Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[4]  C. Buske,et al.  Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Bar,et al.  Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia , 2016, Leukemia & lymphoma.

[6]  D. Neuberg,et al.  Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission , 2016, American journal of hematology.

[7]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[8]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[9]  Alberto Orfao,et al.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.

[10]  J. Cayuela,et al.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.

[11]  W. Stock,et al.  How I treat acute lymphoblastic leukemia in older adolescents and young adults. , 2015, Blood.

[12]  R. Bassan,et al.  Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy , 2015, Current Hematologic Malignancy Reports.

[13]  J. Bourhis,et al.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.

[14]  M. Fumagalli,et al.  Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia , 2015, Haematologica.

[15]  M. Loh,et al.  T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .

[16]  R. Larson,et al.  Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 , 2014 .

[17]  J. Downing,et al.  Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Leber,et al.  Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.

[19]  C. Tam,et al.  A new prognostic score for CLL. , 2014, Blood.

[20]  R. Wade,et al.  Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. , 2014, The Lancet. Oncology.

[21]  A. Cortelezzi,et al.  Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia , 2014, Blood Cancer Journal.

[22]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[23]  R. Bassan,et al.  Current and future management of Ph/BCR-ABL positive ALL , 2014, Expert review of anticancer therapy.

[24]  J. Esteve,et al.  Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Radich,et al.  Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia , 2014, Leukemia research and treatment.

[26]  H. Dombret,et al.  Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL) , 2013 .

[27]  Z. Estrov,et al.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. , 2013, Blood.

[28]  P. Dreger,et al.  Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia , 2013, Leukemia.

[29]  R. Wade,et al.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. , 2013, The Lancet. Oncology.

[30]  M. Kneba,et al.  Has MRD monitoring superseded other prognostic factors in adult ALL? , 2012, Blood.

[31]  E. Thiel,et al.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.

[32]  A. Rambaldi,et al.  Modern therapy of young and adult Ph-ALL. , 2012, Leukemia supplements.

[33]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[34]  T. Barbui,et al.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.

[35]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Kneba,et al.  Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.

[37]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[38]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[39]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[40]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[41]  T. Barbui,et al.  Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Janossy,et al.  Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. , 1981, Leukemia research.